bioRxiv Science⌕ Search

Biology subjects

Gertych, A.

Publications and source records attributed to Gertych, A..

3 recordsLinked to original sources

Spatially resolved transcriptional programs link fallopian tube precursor lesions to immune activation and stromal reorganization

Despite its name, high-grade serous ovarian carcinoma (HGSC) originates in the fallopian tube, not the ovary, arising from a morphologically recognizable precursor lesion, serous tubal intraepithelial carcinoma (STIC). Yet the early cellular and microenvironmental changes driving this transformation remain poorly understood, limiting progress in early detection, interception, and prevention. Here, we generated a Visium HD spatial transcriptomic atlas of fallopian tube carcinogenesis spanning histologically unremarkable fallopian tube epithelium (FTE), STIC, and invasive HGSC. This approach enabled unbiased, tissue-wide, whole-transcriptome mapping at single-cell-level resolution within preserved histologic architecture, providing spatial granularity beyond prior region-of-interest-based platforms. STIC lesions displayed a coordinated epithelial transformation program marked by proliferation, replication stress, DNA repair activation, chromatin remodeling, and induction of tumor-associated antigens, including PRAME and CLDN6, which are emerging targets for vaccine and antigen-directed therapeutic strategies. In contrast, histologically unremarkable FTE contained spatially restricted epithelial defense programs marked by SCGB1A1 and MUC6, suggesting localized protective states that may influence susceptibility to malignant transformation. Using distance- and density-aware spatial analyses, we found that precursor lesions were embedded within immune-enriched, stromal-depleted microenvironments characterized by interferon-dominant immune activation, attenuation of TNF/NF-{kappa}B signaling, macrophage and lymphoid remodeling, and extracellular matrix-associated fibroblast interactions. Computational pathology analysis of collagen architecture confirmed reduced collagen fiber density in STIC-adjacent stroma, linking transcriptomic evidence of stromal remodeling to structural extracellular matrix changes. Together, these data define early epithelial, immune, and stromal programs associated with STIC and identify tumor-associated antigens, epithelial defense states, and immune-stromal niches as candidate targets for HGSC prevention and early interception.

cancer biology↗

Directing iPSC Differentiation into iTenocytes using Combined Scleraxis Overexpression and Cyclic Loading

Regenerative therapies for tendon are falling behind other tissues due to the lack of an appropriate and potent cell therapeutic candidate. This study aimed to induce cell tenogenesis using stable Scleraxis (Scx) overexpression in combination with uniaxial mechanical stretch of mesenchymal stromal cells (MSCs) of different origins. Scleraxis (Scx) is the single direct molecular regulator of tendon differentiation known to date. Mechanoregulation is known to be a central element guiding tendon development and healing. Cells explored were bone marrow-derived (BM-)MSCs as well as MSCs differentiated from induced pluripotent stem cells (iMSCs). Mechanical stimulation combined with Scx overexpression resulted in morphometric and cytoskeleton-related changes, upregulation of early and late tendon markers, increased ECM deposition and alignment, and tenomodulin perinuclear localization in iMSCs, which was greater compared to BM-MSCs and controls. Our findings suggest that these cells can be differentiated into tenocytes and may be a better candidate for tendon cell therapy applications than BM-MSCs.

cell biology↗

RIPK2 Stabilizes c-Myc and is an Actionable Target for Inhibiting Prostate Cancer Metastasis

Despite advances in diagnosis and treatment, metastatic prostate cancer remains incurable and is associated with high mortality rates. Thus, novel actionable drug targets are urgently needed for therapeutic interventions in advanced prostate cancer. Here we report receptor-interacting protein kinase 2 (RIPK2) as an actionable drug target for suppressing prostate cancer metastasis. RIPK2 is frequently amplified in lethal prostate cancers and its overexpression is associated with disease progression and aggressiveness. Genetic and pharmacological inhibition of RIPK2 significantly suppressed prostate cancer progression in vitro and metastasis in vivo. Multi-level proteomic analysis revealed that RIPK2 strongly regulates c-Myc protein stability and activity, largely by activating the MKK7/JNK/c-Myc phosphorylation pathway--a novel, non-canonical RIPK2 signaling pathway. Targeting RIPK2 inhibits this phosphorylation pathway, and thus promotes the degradation of c-Myc--a potent oncoprotein for which no drugs have been approved for clinical use yet. These results support targeting RIPK2 for personalized therapy in prostate cancer patients towards improving survival.

cancer biology↗